Intestinal microbial marker for distinguishing biliary duct cell carcinoma patient from healthy person and application of intestinal microbial marker
By constructing markers of 23 intestinal microbial bacterial species and using fecal samples for metagenomic sequencing, a microbial difference model is established to distinguish patients with cholangiocellular carcinoma from healthy people, solving the problem of early cholangiocellular carcinoma diagnosis and achieving efficient non-invasive diagnosis.
CN119859684APending Publication Date: 2025-04-22THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202411917981.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-12-24
- Publication Date
- 2025-04-22
AI Technical Summary
Technical Problem
The prior art is difficult to effectively diagnose early cholangiocellular carcinoma, and the lack of non-invasive specific diagnostic methods, resulting in the late stage of diagnosis of most patients.
Method used
By constructing a marker composed of 23 intestinal microbial species and using fecal samples for metagenomic sequencing, a microbial difference model is established to distinguish patients with cholangiocellular carcinoma from healthy people.
Benefits of technology
It has achieved differentiated detection of cholangiocellular carcinoma and healthy populations, has high distinction capabilities, is suitable for cross-regional samples in China and around the world, and shows good disease specificity in public data sets.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention belongs to the technical field of biological medicines, and particularly relates to an intestinal microbial marker for distinguishing a bile duct cell carcinoma patient from a healthy person and application of the intestinal microbial marker. The invention provides an enteric microbiological marker for distinguishing a bile duct cell carcinoma patient from a healthy person. The enteric microbiological marker consists of 23 enteric microbiological strains. The intestinal microbial marker disclosed by the invention realizes good distinguishing ability in cholangiocellular carcinoma and healthy people. And the feasibility and applicability of the distinguishing model are verified in cross-regional samples in China. In addition, the distinguishing model achieves good disease specificity in a common data set queue of 11 diseases from the world.
Need to check novelty before this filing date? Find Prior Art